Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone

@article{BartosikPsujek2011TotalTA,
  title={Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone},
  author={Halina Bartosik-Psujek and Marek Psujek and Jacek Jaworski and Zbigniew Stelmasiak},
  journal={Acta Neurologica Scandinavica},
  year={2011},
  volume={123}
}
Bartosik‐Psujek H, Psujek M, Jaworski J, Stelmasiak Z. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand: 2011: 123: 252–256. © 2010 John Wiley & Sons A/S. 
View on Wiley
ff.ul.pt
39 Citations
Highly Influential Citations
1
Background Citations
14
Methods Citations
2
Results Citations
3

39 Citations

Citation Type

Citation Type

Role of S100B on central nervous system demyelination and remyelination
Tese de mestrado, Ciencias Biofarmaceuticas, Universidade de Lisboa, Faculdade de Farmacia, 2014
Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis–osteopontin as a potential marker of clinical severity
S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis
TLDR
Overall, high S100B expression in MS patient samples suggests its usefulness as a diagnostic biomarker for MS, while the beneficial outcome of its inhibition in the demyelinating model indicates S 100B as an emerging therapeutic target in MS.
Science is 1% inspiration and 99% biomarkers
TLDR
Six promising neurodegenerative biomarkers in MS are described and critically evaluating the evidence using a modified Bradford Hill criteria are critically evaluated.
BDNF and Tau as biomarkers of severity in multiple sclerosis.
TLDR
BDNF is a good biomarker for diagnosis of MS but not for severity or progression, and Tau appears to have a more active role in the progression of MS.
BDNF and Tau as biomarkers of severity in Multiple Sclerosis
TLDR
Tau was increased in RRMS, in the second decile of the MSSS and even in the lowest EDSS, and tau returns to normal levels, suggesting an active role for this protein in MS, and BDNF levels were lower in all MS patients, compared to healthy controls.
The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis
TLDR
Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients, while the serum S 100B levels did not differ between patients with active disease or in remission.
Altered gastrointestinal motility involving autoantibodies in the experimental autoimmune encephalomyelitis model of multiple sclerosis
  • E. Spear, E. Holt, +7 authors G. Mawe
  • Medicine, Biology
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2018
TLDR
Diagnosis of gastrointestinal dysmotility in the experimental autoimmune encephalomyelitis mouse model of MS is characterized and whether autoantibodies target the enteric nervous system (ENS) and cause Dysmotility is evaluated.
Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders
TLDR
The present review summarizes the role of S100B in various neurological disorders and potential therapeutic measures to reduce the prevalence of neurological disorders.
Autoantibodies against myelin sheath and S100β are associated with cognitive dysfunction in patients with rheumatoid arthritis
TLDR
The data indicate that autoantibodies against myelin basic protein, myelin oligodendrocyte glycoprotein, and S100β may be harmful to proper cognitive function and RA is associated with impaired cognitive performance associated with higher levels of CNS-related autoantibia levels.
...
1
2
3
4
...

References

SHOWING 1-10 OF 24 REFERENCES
Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis
TLDR
This study aimed to demonstrate the association between cerebrospinal fluid (CSF) tau protein concentrations and clinical prognosis in MS patients.
Plasma S100β and NSE levels and progression in multiple sclerosis
Plasma S100beta and NSE levels and progression in multiple sclerosis.
TLDR
It is found that plasma NSE levels were lower in patients with clinically relevant worsening on the Expanded Disability Status Scale (EDSS), defined as 1 point increase from EDSS <6.0 or 0.5 point increase after five years, and in Patients with a progressive disease course.
Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG
TLDR
The hypothesis that inflammation may be at least in part responsible for the axonal damage observed in MS patients is strengthened.
Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis
TLDR
The objective of the present study was to elucidate whether CSF tau levels could be a marker of MS activity.
Increased Cerebrospinal Fluid Tau Protein in Multiple Sclerosis
TLDR
Examination of microtubule-associated protein tau in the cerebrospinal fluid of patients with MS vs. controls may indicate axonal impairment in a subpopulation of MS patients and may provide a tool for the estimation of axonal damage during life.
Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis
TLDR
This study showed similar CSF tau concentrations in MS patients with different clinical characteristics, suggesting that tau protein does not seem to be a useful routine clinical marker of axonal damage.
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.
TLDR
It is found that S100B is a good marker for the relapsing phase of the disease as opposed to ferritin, which is elevated throughout the entire course, and GFAP correlated with disability scales and may therefore be a marker for irreversible damage.
Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis
TLDR
No significant difference among different subtypes of MS could be detected, although highest levels were found in very early disease stages and a tendency towards higher CSF tau levels in patients with pronounced intrathecal IgG synthesis is supported, supporting the notion that axonal damage is influenced by inflammatory activity.
...
1
2
3
...